PCSK-9 inhibition in patients with recalcitrant hypercholesterolemia has reaped reductions in LDL-C of up to 85% after the first week of therapy.
Robert Giugliano, MD
Advertisement
Articles by Robert Giugliano, MD
Advertisement
Latest Updated Articles
- Lipid-lowering Injectable Antibodies: The Next Big Thing?
Published: November 29th 2012 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Clears First At-Home Brain-Stimulation Device for Major Depression
2
New AI Tool Detects Missed Alzheimer Disease Diagnoses, Reduces Disparities
3
Adult Stimulant Use Accounts for Most Recent Growth in ADHD Prescribing in Canada
4
Retatrutide Achieves Up to 28.7% Weight Loss and Marked Knee Pain Reduction in Phase 3 TRIUMPH-4 Trial
5
